The Chicago Entrepreneur

Merck shares drop 10% as pharma giant scraps trial of promising cancer drug

Merck & Co called off a Phase III trial of its promising cancer drug Xevinapant after an independent panel concluded it is unlikely to meet its goals

Previous post Treasury yields hold in tight range as traders await data
Next post Don’t miss this 1929 Hudson River home of Michael Douglas and Catherine Zeta-Jones, listed for $12 million